Slide 1: Result presentation Q3/2021
4 November 2021, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q3/2021
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights Q3-2021
Revenue stable: Western markets continued strong growth, no new camera 1. deliveries to China during the quarter. Highlights Q3-2021 Software: Software segment made another growth record during the quarter, 2. over 20 percent. Clinical Trial: We are expecting to receive the results from the US clini
Slide 4: Focus areas
Focus areas China: • No new camera deliveries to China during the quarter • Currently it is hard to forecast revenue and the long- term potential can only be assessed during 2022 USA: • Strong growth in the US market • The clinical trials with the aim to the FDA approval for Aurora AEYE, a handheld
Slide 5: Q3/2021 Financial highlights (KEUR)
Q3/2021 Financial highlights (KEUR) Q3/2021 Q3/2020 Change Revenue 3,342 3,338 0.1% Gross profit 1) 2,250 2,262 -0.5% Gross margin 2) 67.3% 67.8% -0.5 bps Adjusted EBITDA -337 229 -247.2% Adjusted EBITDA margin -10.1% 6.9% -17.0 bps Net profit/ loss -833 -299 -178.4% Earnings per share -0.06 -0.02 -
Slide 6: 1-9/2021 Financial highlights (KEUR)
1-9/2021 Financial highlights (KEUR) 1-9/2021 1-9/2020 Change Revenue 11,299 8,969 26.0% Gross profit 1) 8,151 6,146 32.6% Gross margin 2) 72.1% 68.5% +3.6 bps Adjusted EBITDA -475 -671 29.3% Adjusted EBITDA margin -4.2% -7.5% 3.3 bps Net profit/ loss -2,313 -2,525 8.4% Earnings per share -0.17 -0.1
Slide 7: Devices segment highlights
Devices segment highlights OPT@MED
Slide 8: Devices segment highlights
Q3/2021 Q3/2020 Change No hardware deliveries were made to 1. China due to initial inventory deliveries in the first half of the year Devices segment highlights Revenue 1,167 1,537 -24.1% North America and European Gross profit 722 933 -22.6% 2. markets continued strong growth as well as sales the O
Slide 9: Devices Segment 1-9/2021 financials
Devices Segment 1-9/2021 financials 1-9/2021 1-9/2020 Change % Revenue 4,510 3,359 34.3% Gross profit 3,375 1,872 80.3% Gross margin 74.8% 55.7% 19.1 bps EBITDA 184 -251 173.2% EBITDA margin 4.1% -7.5% 11.6 bps
Slide 10: Software segment highlights
Software segment highlights
Slide 11: Software segment highlights
Q3/2021 Q3/2020 Change Software segment highlights Record growth for the software Revenue 2,176 1,802 20.8% 1. segment Gross profit 1,528 1,330 14.9% Drivers included screening and Gross margin 70.3% 73.8% -3.5 bps workflow software deliveries to 2. new customers as well as increase in recurring rev
Slide 12: Software Segment 1-9/2021 financials
Software Segment 1-9/2021 financials 1-9/2021 1-9/2020 Change % Revenue 6,789 5,610 21.0% Gross profit 4,776 4,274 11.7% Gross margin 70.4% 76.2% -5.8 bps EBITDA 1,339 1,291 3.7% EBITDA margin 19.7% 23.0% -3.3 bps
Slide 13: Outlook 2021
| y Outlook 2021
Slide 14: Outlook 2021
Outlook 2021 Optomed expects its full year 2021 revenue to grow strongly compared to 2020 (Announced 8 April 2021)
Slide 15: Financial targets
Financial targets Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an aver
Slide 16: Balance sheet
Balance sheet 30/9 2021 30/9 2020 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 5,375 5,386 • Equity ratio of 62.7 (66.5) percent Other intangible assets 2,537 2,910 Total intangible assets 12,528 12,552 • Total borrowings of EUR 6.8 (6.5) Total tangible assets 1,347 1,129 million. New
Slide 17: Cash flow
Cash flow Q3 2021 Q3 2020 Loss for the financial year -833 -299 Cash flows before change -207 306 in net working capital Change in net working capital -541 -692 • Cash flow from operating activities amounted to EUR -0.8 (-0.4) million Cash flows before finance items -748 -386 Cash flows from finance
Slide 18: Optomed's mission is to prevent blindness
“ Optomed’s Expansion into new geographical markets mission is to prevent blindness by improving access to eye screening Opening new customer segments: primary care globally Bringing AI-integrated health screening to the market
Slide 19: Appendix
Appendix
Slide 20: Cash flow 1-9/2021
Cash flow 1-9/2021 1-9 2021 1-9 2020 Loss for the financial year -2,313 -2,525 Cash flows before change in net working capital -134 -457 Change in net working capital -2,239 -2,512 Cash flows before finance items -2,373 -2,969 Cash flows from finance items -77 -246 Net cash from operating activities